reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TXN TEXAS INSTRUMENTS INCORPORATED
TRN TRINITY INDUSTRIES INC.
THRM GENTHERM INCORPORATED
TER TERADYNE INC.
SLAB SILICON LABORATORIES INC.
SCL STEPAN COMPANY
ROG ROGERS CORPORATION
ROCK GIBRALTAR INDUSTRIES INC.
RBC REGAL BELOIT CORP
PCAR PACCAR INC
MGPI MGP INGREDIENTS INC.
LFUS LITTELFUSE INC.
LEN LENNAR CORPORATION CLASS A
KWR QUAKER CHEMICAL CORPORATION
IOSP INNOSPEC INC.
CGNX COGNEX CORPORATION
CCS CENTURY COMMUNITIES INC.
BZH BEAZER HOMES USA INC.
BCC BOISE CASCADE CO.
AOSL ALPHA & OMEGA SEMICONDUCTOR
AMPH AMPHASTAR PHARMACEUTICALS INC
ALB ALBEMARLE CORPORATION
MHK MOHAWK INDUSTRIES INC.
MG/CN MAGNA INTERNATIONAL INC.
BC BRUNSWICK CORPORATION
AMWD AMERICAN WOODMARK CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
MLHR HERMAN MILLER INC.
NX QUANEX BUILDING PRODUCTS CORPORATION
TNC TENNANT COMPANY
SITE SITEONE LANDSCAPE SUPPLY INC.
ICHR ICHOR HOLDINGS LTD.
APLS APELLIS PHARMACEUTICALS
YETI YETI HOLDINGS
HLIO HELIOS TECHNOLOGIES INC.
MBC_w MASTERBRAND INC
ZK ZEEKR INTELLIGENT TECHNOLOGY HOLDING LIMITED
TE ALUSSA ENERGY ACQUISITION CORP
American Assets Trust, Inc. Announces First Quarter 2025 Earnings Rele...
American Assets Trust, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its first quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, April 29, 2025. Senior management will hold a conference call for its first quarter 2025 earnings on Wednesday, April 30, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc...
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Board of Directors during...
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial ...
American Assets Trust, Inc. Acquires Genesee Park Apartments in San Di...
American Assets Trust, Inc. Acquires Genesee Park Apartments in San Diego, California SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the successful acquisition of Genesee Park, a 192-unit apartment community located in San Diego, California. Genesee Park is currently approximately 93% leased with rental rates that the Company believes are significantly below prevailing market levels for the submarket. The acquisition presents a compelling opportunity to enhance the property’s value through strategic asset management in...
American Assets Trust, Inc. Announces Sale of Del Monte Shopping Cente...
American Assets Trust, Inc. Announces Sale of Del Monte Shopping Center in Monterey, California SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) announced today the sale of Del Monte Shopping Center, a premier retail destination in Monterey, California, for approximately $123.5 million, before closing prorations. "The sale of Del Monte Center is a strategic decision that allows us to focus on markets where we can achieve greater economies of scale and operational efficiencies while aligning with our long-term growth objectives. We are pr...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webcasts and replays, when av...
American Assets Trust, Inc. Reports Fourth Quarter and Year End 2024 F...
American Assets Trust, Inc. Reports Fourth Quarter and Year End 2024 Financial Results Net income available to common stockholders of $9.0 million and $56.8 million for the three months and year ended December 31, 2024, respectively, or $0.15 and $0.94 per diluted share, respectively. Funds from Operations ("FFO") per diluted share decreased 4% and increased 8% year-over-year for the three months and year ended December 31, 2024, respectively, to $0.55 and $2.58 per diluted share, respectively. Introducing 2025 annual guidance midpoint of $1.94 with a range of $1.87 to $2.01 o...
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare ...
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. Live webcast and replay can be found under "News / Events" in the Investors...
American Assets Trust, Inc. Releases Tax Status of 2024 Distributions
American Assets Trust, Inc. Releases Tax Status of 2024 Distributions SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the tax treatment of its 2024 dividend distributions as follows: Security Descriptions: Common StockCUSIP: 024013104Ticker Symbol: AAT Record DatePayable DateTotal Distribution Per ShareAllocable to 2024Taxable Ordinary DividendLT Capital GainUnrecaptured Sec. 1250 GainSection 199A DividendsReturn of Capital03/07/2403/21/24$0.335$0.335$0.273097$0.000000$0.000000$0.273097$0.06190306/06/2406/20/24$0.335$0....
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2024...
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2024 Earnings Release Date and Conference Call Information SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2024 earnings in a press release to be issued after the market closes on Tuesday, February 4, 2025. Senior management will hold a conference call for its fourth quarter and year-end 2024 earnings on Wednesday, February 5, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 a...
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. “We are thrilled to welcome Jennifer to ...
Louisiana-Pacific Corp: 1 director
A director at Louisiana-Pacific Corp sold 2,500 shares at 113.495USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
American Assets Trust Inc: 4 directors
Four Directors at American Assets Trust Inc sold 35,915 shares at between 0.000USD and 28.220USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Ex...
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full ex...
Avalo Therapeutics to Present at Upcoming Investor Conferences
Avalo Therapeutics to Present at Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference, New YorkMonday, November 18, 2024 at 3:35 PM ET Piper Sandler 36th Annual Healthcare Conference, New YorkWednesday, December 5, 2024 at 11:00 AM ET Live we...
Avalo Reports Third Quarter 2024 Financial Results and Recent Business...
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatmen...
American Assets Trust, Inc. Reports Third Quarter 2024 Financial Resul...
American Assets Trust, Inc. Reports Third Quarter 2024 Financial Results Net income available to common stockholders of $16.7 million and $47.8 million for the three and nine months ended September 30, 2024, respectively, or $0.28 and $0.79 per diluted share, respectively. Funds from Operations ("FFO") per diluted share increased 20% and 10% year-over-year for the three and nine months ended September 30, 2024, respectively, to $0.71 and $2.03 per diluted share, respectively. Increased 2024 FFO per diluted share guidance to a range of $2.51 to $2.55 with a midpoint of $2.53, a 1% incr...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Louisiana-Pacific Corporation ("LP") and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 21 October 2024 in which we reassessed the appropriateness of the rati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.